Department of Osteoporosis, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, China.
Center for Clinical Precision Medication, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510006, China.
J Ethnopharmacol. 2020 Oct 28;261:113113. doi: 10.1016/j.jep.2020.113113. Epub 2020 Jul 12.
Morinda officinalis is a well-known Chinese tonic herb that has shown clinical efficacy in the treatment of bone disease. However, its anti-osteoporotic potential and the M. officinalis polysaccharides (MOPs) responsible for activity require further investigation.
This study aimed to investigate the anti-osteoporotic effects of different MOP fractions in ovariectomized (OVX) rats, and to identify the osteoprotective components by bioassay-guided isolation.
MOPs were prepared by hot water and alkali extraction, separated into three fractions (MO50, MO70, and MOB) and evaluated in the classic OVX rat model and in MC3T3-E1 cells for anti-osteoporotic activity.
Administration of MOPs (400 mg/kg/day) provided significant protection against ovariectomy-induced bone loss and biomechanical dysfunction in rats. Treated animals exhibited reduced deterioration of trabecular microarchitecture and lower levels of bone turnover markers. Bioactivity-guided fractionation led to the isolation of two inulin-type fructans from MO50, MOW50-1 and MOP50-2, with potential anti-osteoporotic activities. These consisted of (2 → 1)-linked β-D-fructosyl residues with degrees of polymerization (DP) of 7 and 13, respectively. Furthermore, MOW50-1 promoted osteogenic differentiation of MC3T3-E1 cells by increasing alkaline phosphatase activity.
These data suggest very strongly that MOPs, especially MO50 and MOW50-1, may play important roles in the prevention and treatment of osteoporosis.
桑黄是一种广为人知的中国滋补草药,已在治疗骨病方面显示出临床疗效。然而,其抗骨质疏松的潜力和负责活性的桑黄多糖(MOPs)需要进一步研究。
本研究旨在探讨不同 MOP 级分对去卵巢(OVX)大鼠的抗骨质疏松作用,并通过生物测定指导分离鉴定具有骨保护作用的成分。
采用热水和碱提取法制备 MOPs,将其分为三个级分(MO50、MO70 和 MOB),并在经典的 OVX 大鼠模型和 MC3T3-E1 细胞中评价其抗骨质疏松活性。
MOPs(400mg/kg/天)给药对去卵巢大鼠的骨丢失和生物力学功能障碍提供了显著的保护作用。治疗动物表现出小梁微结构恶化的减少和骨转换标志物水平的降低。基于生物活性的分级分离从 MO50 中分离出两种菊糖型果聚糖,MOW50-1 和 MOP50-2,具有潜在的抗骨质疏松活性。它们由(2→1)-连接的β-D-果糖基残基组成,聚合度分别为 7 和 13。此外,MOW50-1 通过增加碱性磷酸酶活性促进 MC3T3-E1 细胞的成骨分化。
这些数据强烈表明 MOPs,特别是 MO50 和 MOW50-1,可能在骨质疏松症的预防和治疗中发挥重要作用。